FUNCTIONAL AREAS – Page 18

Incomplete impact assessment during requalification planning – regulatory deficiency analysis and remediation roadmap

Identifying early signals of incomplete impact assessments is key to mitigating risks associated with requalification. Symptoms may present themselves in various forms:Click to read the full article.

PPQ acceptance criteria not met during inspection readiness – how to prevent repeat validation failures

Identifying early warning signs is crucial when PPQ acceptance criteria are at risk of failing. Symptoms may manifest during routine checks or as part of an internal audit. Key indicators…

Incomplete impact assessment during inspection readiness – documentation pitfalls that trigger 483 observations

Signs of incomplete impact assessments typically emerge in both manufacturing and laboratory environments. Here are a few key symptoms that may indicate a problem:Click to read the full article.

CSV not aligned to actual use during validation lifecycle – risk-based validation strategy aligned to FDA/EMA

Aligning CSV to Actual Use in the Validation Lifecycle: An Investigation Guide In the complex arena of pharmaceutical operations, the alignment of Computerized System Validation (CSV) with actual use during…

Incomplete impact assessment during validation lifecycle – how to rebuild the evidence package for inspectors

Identifying symptoms of incomplete impact assessments is crucial for a timely response. Typically, symptoms can manifest in various forms, including:Click to read the full article.

CSV not aligned to actual use during system upgrades – documentation pitfalls that trigger 483 observations

Identifying early signals or symptoms of CSV misalignment during system upgrades is paramount. Signs may vary across production batches and depend on specific operational environments, but some common indicators include:Click…

Inadequate worst-case justification during requalification planning – how to prevent repeat validation failures

Identifying symptoms or signals is the first step in addressing inadequate worst-case justification during requalification. These signals may arise during different phases of manufacturing and validation processes, including:Click to read…

Incomplete impact assessment during validation lifecycle – documentation pitfalls that trigger 483 observations

Identifying early warning signals of an incomplete impact assessment is vital for timely intervention. Symptoms can manifest in various aspects of the operation or documentation. Here are typical signals to…

Inadequate worst-case justification during validation lifecycle – how to rebuild the evidence package for inspectors

The first indication of inadequate worst-case justification often arises from the regulatory inspection feedback or internal audits. Common symptoms include:Click to read the full article.

Inadequate worst-case justification during requalification planning – documentation pitfalls that trigger 483 observations

Deficiencies in Worst-Case Justification During Requalification Planning: Mitigating Risks of Regulatory Observations In the pharmaceutical manufacturing environment, requalification represents a critical component in maintaining compliance with Good Manufacturing Practices (GMP).…

Protocol deviation not investigated during system upgrades – regulatory deficiency analysis and remediation roadmap

Identifying the symptoms or signals indicating potential deficiencies in protocol investigation during system upgrades is the initial step in addressing compliance issues. Common signals may include:Click to read the full…

Traceability matrix gaps during requalification planning – how to rebuild the evidence package for inspectors

Recognizing the initial signals or symptoms related to gaps in traceability matrices is crucial for initiating a prompt investigation. The following symptoms may indicate potential issues:Click to read the full…